Systemic therapy in primary angiosarcoma of the spleen

Bruna Pellini Ferreira, Eve T. Rodler, Elizabeth T. Loggers, Seth M. Pollack, Robin L. Jones

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Primary splenic angiosarcoma is a very rare neoplasm with a high propensity for metastatic disease and poor prognosis. There is a paucity of literature concerning this specific sarcoma subtype and the role of systemic therapy is not well defined. A retrospective review of the prospectively maintained University of Washington/Seattle Cancer Care Alliance Sarcoma Unit database was performed to identify patients with splenic angiosarcoma treated between 2007 and 2012. In total there were 19 patients with angiosarcoma treated at the Seattle Cancer Care Alliance from 2007 to 2012. The number of patients with splenic angiosarcoma was 2 (11%). The first patient was a woman aged 57 years who was referred with metastatic splenic angiosarcoma to the liver, post-splenectomy. She was treated with 4 cycles of weekly paclitaxel prior to metastatic resection and 4 cycles of the same drug in an adjuvant scenario, achieving a pathological complete response to treatment. She is alive and on third-line systemic therapy. The second patient was a male patient aged 30 years who presented with metastatic high-grade splenic angiosarcoma and was treated with 3 lines of systemic therapy, including doxorubicin, paclitaxel and gemcitabine+docetaxel, but developed a gastrointestinal metastasis with subsequent gastrointestinal bleeding. Splenic angiosarcoma is a very rare neoplasm. Surgery remains the mainstay of management for localized disease. Paclitaxel administered weekly proved to be well-tolerated and resulted in a good radiological response in one of our patients, enabling resection of metastatic disease. Durable clinical benefit can be achieved in metastatic splenic angiosarcoma with multi modality management.

Original languageEnglish (US)
Pages (from-to)178-180
Number of pages3
JournalRare Tumors
Issue number4
StatePublished - 2012
Externally publishedYes


  • Anthracycline
  • Paclitaxel
  • Splenic angiosarcoma
  • Systemic therapy

ASJC Scopus subject areas

  • Histology
  • Oncology


Dive into the research topics of 'Systemic therapy in primary angiosarcoma of the spleen'. Together they form a unique fingerprint.

Cite this